19 - 20 November 2015 | Philadelphia, PA
At eyeforpharma's 3rd annual Customer Engagement Summit delegates will learn how to engage their key customers through a wide range of channels – from digital to F2F. More info here...

Thursday, September 17, 2015

mHealth Apps: Overwhelming Choice, Limited Proven Efficacy, Security Issues

According a new study just released by the IMS Institute for Healthcare Informatics, the number of mobile health applications (mHealth apps) available to consumers now surpasses 165,000. The study, Patient Adoption of mHealth: Use, Evidence and Remaining Barriers to Mainstream Acceptance, analyzed 26,864 apps available in the U.S. Apple iTunes and Android app stores -- a representative sample of the most widely used mHealth apps by consumers.

The problem is this: too many apps, too little efficacy in terms of health outcomes.

"The fast-paced growth of the healthcare app market has outpaced the ability to develop oversight and guidance for accuracy of clinical content contained in mHealth apps," concludes the report. "The sheer volume of choices in the consumer mHealth apps available in the absence of a mechanism for certifying or ranking apps leaves providers and consumers on their own to navigate app selection. This environment leads to provider reluctance in prescribing mHealth apps given the unknowns about accuracy, efficacy as well as security."

What's the solution?

Wednesday, September 16, 2015

Some - Not All - Americans Hate Pharma More Than Ever, Says Gallup Poll

The story came to me via Google Alerts: "People in the US Hate Big Pharma, Study Finds." At first, my reaction was Duh! Nothing to see here, considering all the pushback from physicians and other stakeholders (including patients?) regarding high drug prices.

I clicked through anyway to the story on teleSUR (a Latin American multimedia platform - how does it get included in Google Alerts whereas this blog does not?). Perhaps something was lost in translation - perhaps a better translation would have been the title I'm using for this post. 

In any case, here's the trending data direct from Gallup (here), which surveyed 1,011 U.S. adults in in the first week of August 2015 via telephone:

Click on image for an enlarged view.

IMHO, the saw-tooth trend indicates a love-hate relationship. Last year (2014) pharma gained respect, this year it lost it - but not as much as in most previous years. 

Also, there are some segments of the population that have a positive view of the pharmaceutical industry. Can you guess who?

Tuesday, September 15, 2015

As J&J Focuses Less on Consumer Products and More on Medical Devices & Rx Drugs, Its Image Gets More Tarnished

JNJ has always positioned itself as a "consumer" products company, but its main business is pharmaceutical drugs and medical devices. According to a Q2 2015 financial statement (here), Rx products account for 45% of the company's sales, medical devices 36%, and consumer products - for which the company is loved - only 19% (see chart on left).

In Q1 of 2012 the percentages were 37%, 40%, and 23% (see here).

I am interested in this because of data regarding J&J's PROFITS that I came across in a article by journalist Steven Brill today in The Huffington Post Highline titled "America’s Most Admired Law Breaker."

That article is part of a 15-part "DocuSerial" detailing how Johnson & Johnson took an anti-psychotic drug, Risperdal, initially intended only for the treatment of psychotic disorders, and put it in the hands of children and the elderly in violation of FDA restrictions. Of course, I've written about J&J's illegal activities many time now here on Pharma Marketing Blog (read, for example, "How J&J's Alex Gorsky Tried to Negotiate a Smaller DOJ Fine").

But what about J&J's profits? Where do they come from? What's the impact on the company's reputation?

Tuesday, September 08, 2015

Join Me at the STEM 4 Health Berlin Meetup on September 23

"It is a pleasure to have Pharmaguy, aka John Mack, visiting us in Berlin again!,"says Jesus del Valle Rosales, Head of Bayer's Grants4Apps Digital Health Accelerator. "Pharmaguy has been at the forefront of digital marketing for the pharmaceutical industry since the early days, Twitter pioneer, and as a constructive pharma observer his writings are both followed and dreaded by many in the industry. Welcome to Berlin, John!"

Hmmm... "dreaded" may be a bit strong. I would say "respected" as someone who speaks truth to power. After all, Pharma Brands Benefit from "Mack Attacks."
I will receive a small honorarium from Bayer to make this presentation.

Wednesday, September 02, 2015

Will the REAL Nexium Facebook Page Please Stand Up?

My friend Zoe Dunn (@zdunnhealth), a digital marketing consultant to the pharma industry, wrote a piece in MM&M titled “Is It Finally Time for Pharma to Change the Way It Uses Facebook?” (see here).

In that article, Zoe chides the pharma industry for not engaging and supporting users of their Rx drugs via Facebook.

“Pharma has hidden behind the ability to turn commenting off on Facebook pages,” Zoe notes, “allowing marketers to use the channel much as they would a typical web page.”

A good example of how an Rx brand should use Facebook, according to Zoe, is the Nexium FB page. “Look at what the team behind acid-reflux medication Nexium has done, for example. The brand has had an 'open' branded Facebook page from the very moment the page launched late last year.”

Unfortunately, the article did not include a link to the Nexium Facebook page she was talking about. I had to fend for myself and do a search on Facebook. Guess what I found.

Related Posts Plugin for WordPress, Blogger...